Mifepristone

What Is Mifepristone

Mifepristone is a prescription drug that blocks progesterone, a hormone a pregnancy needs to continue. It is used in a two-drug regimen with a second medication, misoprostol, to end an early pregnancy, approved for use through 10 weeks. Doctors also use it to manage miscarriage and to treat Cushing’s syndrome.

The two drugs do different jobs, which is why the regimen matters. Mifepristone ends the pregnancy by blocking progesterone, and misoprostol, taken hours to a day later, causes the uterus to cramp and empty. Together they are 93 to 99% effective through 10 weeks.

How Safe It Is

Mifepristone is one of the most-studied drugs in the country, and serious complications are rare. A large California study of Medi-Cal patients found a 0.31% major-complication rate. Reported deaths run about 5 per million users, and the FDA says those reported deaths cannot be reliably attributed to the drug itself.

The leading medical groups agree on the science. The American College of Obstetricians and Gynecologists and the American Academy of Family Physicians affirm that mifepristone is safe and effective, and ACOG and other organizations reaffirmed that position in May 2025. For scale, acetaminophen, the active ingredient in Tylenol, is linked to far more deaths in the U.S. each year than mifepristone.

The numbers behind that record are worth seeing together.

That 25-year record is the heart of the legal and political fight. The question in court is not really whether the drug is safe, because the evidence on that is settled. The question is who gets to decide how it is dispensed.

What the Supreme Court did and did not decide in June 2024. Source: Supreme Court, FDA v. Alliance for Hippocratic Medicine.

Question	What the Court did
Did the challengers have standing to sue	No. The Court ruled 9-0 that they were not harmed by the FDA’s rules.
Did the Court rule on whether mifepristone is safe	No. It did not reach the medical or scientific question at all.
Did the Court change the FDA’s rules	No. Telehealth, mail, and pharmacy dispensing stayed in place.
Did the case end	No. It continues in a Texas federal court with three states as plaintiffs.

The table makes the limit of the ruling clear. The justices threw the case out on a procedural ground, standing, and left every substantive question open for the next round.

The Access Rules

How you can get mifepristone has loosened steadily since 2000, and that loosening is what opponents are fighting to reverse. The FDA originally required patients to pick up the drug in person at a clinic or hospital. The agency removed that in-person rule in December 2021, which allowed prescriptions by telehealth and delivery by mail.

The agency went further in January 2023 by letting certified retail pharmacies dispense the drug. Prescribers and patients still have to sign agreement forms documenting the prescription, so the drug is not handed out without a clinician. These rules are collectively called the REMS, the FDA’s Risk Evaluation and Mitigation Strategy for the drug.

The telehealth change reshaped how Americans get abortion care. By the end of 2024, about 1 in 4 abortions in the country were done through telehealth, often with pills mailed to the patient. That shift is exactly what the current lawsuit and the Comstock argument aim to undo.

The Supreme Court Fight

Mifepristone’s legal arc runs from approval to mail access to a unanimous Supreme Court win that did not end the fight. The drug was approved in 2000, cleared for mail in 2021 and retail pharmacies in 2023, survived a 9-0 standing ruling in June 2024, then ran into a new FDA safety review in 2025, a wave of states reaching across their borders to prosecute shield-law doctors, and a 2026 Supreme Court order that kept mail access in place while the fight continues.

1. 2000 FDA approves mifepristone Cleared for ending early pregnancy in a two-drug regimen.
2. 2021 FDA allows it by mail The in-person pickup rule is dropped, opening telehealth and mail delivery.
3. 2023 Retail pharmacies can dispense it Certified pharmacies are allowed to fill mifepristone prescriptions.
4. June 2024 Supreme Court rejects the challenge A 9-0 ruling says the plaintiffs lacked standing; the rules stay.
5. 2025 New FDA safety review announced, then delayed HHS and the FDA pledge a review; reporting says it stalls.
6. 2025 States reach across state lines Texas and Louisiana pursue a New York shield-law doctor.
7. May 2026 Supreme Court keeps mail access for now The justices let telehealth and mail delivery continue while a new challenge proceeds.

Sources: FDA; Guttmacher Institute; Supreme Court.

Mifepristone from approval to courtroom, 2000 to 2026: 2000 — FDA approves mifepristone (Cleared for ending early pregnancy in a two-drug regimen.). 2021 — FDA allows it by mail (The in-person pickup rule is dropped, opening telehealth and mail delivery.). 2023 — Retail pharmacies can dispense it (Certified pharmacies are allowed to fill mifepristone prescriptions.). June 2024 — Supreme Court rejects the challenge (A 9-0 ruling says the plaintiffs lacked standing; the rules stay.). 2025 — New FDA safety review announced, then delayed (HHS and the FDA pledge a review; reporting says it stalls.). 2025 — States reach across state lines (Texas and Louisiana pursue a New York shield-law doctor.). May 2026 — Supreme Court keeps mail access for now (The justices let telehealth and mail delivery continue while a new challenge proceeds.).

2000: The FDA approved mifepristone for ending early pregnancy. In 2016 the agency extended approval through 10 weeks of pregnancy and updated the dosing based on years of use.

2021: In December 2021, the FDA permanently removed the requirement that patients pick up the drug in person, which made telehealth prescriptions and mail delivery possible nationwide.

2023: In January 2023, the FDA allowed certified retail pharmacies to dispense mifepristone, so patients could fill a prescription the way they fill any other.

June 2024: In FDA v. Alliance for Hippocratic Medicine, the Supreme Court ruled 9-0 on June 13, 2024, that the anti-abortion doctors and groups who sued lacked standing. The Court did not rule on whether the drug is safe and left the FDA’s rules in place.

2025: HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary pledged in September 2025 that the FDA would review mifepristone’s safety. Bloomberg reported in December 2025 that the review had been delayed.

2025: States with abortion bans began reaching across state lines. Texas won a civil judgment of more than $100,000 against New York doctor Margaret Carpenter, and Louisiana criminally indicted her, while New York refused to cooperate under its shield law.

May 2026: The Supreme Court let telehealth and mail access continue, staying a Fifth Circuit ruling that would have required in-person visits, while a new challenge led by Louisiana proceeds.

Where It Stands Now

As of June 2026, mifepristone is still legal and still available by telehealth and mail, but the ground is shifting underneath it. In May 2026 the Supreme Court let telehealth and mail access continue while a new challenge led by Louisiana moved forward, the latest in a string of fights the drug has survived but not ended. The same case the Supreme Court tossed continues in the Northern District of Texas before Judge Matthew Kacsmaryk, this time with Missouri, Idaho, and Kansas as state intervenors who want to roll back telehealth and mail access.

Two newer threats run alongside the lawsuit. The FDA’s promised safety review, announced in September 2025, would give the agency a path to tighten the rules without Congress, though reporting in December 2025 said the review had stalled. The 1873 Comstock Act, a dormant anti-vice law that bans mailing items used for abortion, is being revived to argue that sending the pills is already a federal crime.

State shield laws are the counterweight. New York, California, and other states have passed laws protecting doctors who prescribe to patients in ban states, which is why New York could refuse to hand over Dr. Carpenter. Whether one state can punish a doctor licensed and practicing legally in another is now headed for the courts.

Why It Matters

Mifepristone matters because it is how most Americans end a pregnancy and manage a miscarriage, and access to it now depends on a court fight rather than on the medicine. About 63% of abortions use pills, and millions of people have relied on the drug across 25 years and both parties’ administrations.

The threat is real, but so is the defense. The drug’s safety record is not in serious scientific dispute, the leading OB-GYN and family-medicine groups back it, and the Supreme Court left it on the market. Shield laws, telehealth networks, and the FDA’s own evidence are all standing between the drug and the people trying to restrict it.

The Honest Disagreement

Serious people disagree about mifepristone, and the disagreement is worth laying out plainly. We present both cases and let you weigh them.

The case for restriction comes from groups like the Alliance for Hippocratic Medicine and several Republican state attorneys general. They argue that the FDA loosened important safeguards when it allowed telehealth and mail without an in-person visit, that remote prescribing raises safety and oversight concerns, and that the 1873 Comstock Act already makes mailing abortion drugs illegal. In their view the agency moved too far, too fast.

The case for access comes from the FDA, the American College of Obstetricians and Gynecologists, and the American Academy of Family Physicians. They point to a 25-year safety record, a major-complication rate well under 1%, and decades of data showing telehealth dispensing is safe. They argue the restrictions are political rather than scientific, aimed at a drug the evidence has repeatedly cleared.

Where the medical evidence is not split is on safety itself. The studies, the FDA’s own findings, and the major physician groups agree the drug is safe and effective through 10 weeks. The fight is over who controls how it is dispensed and whether a 19th-century law can reach a 21st-century prescription, not over whether the medicine works.

Frequently asked questions

Is mifepristone safe? Yes, by the available evidence. A large study found a 0.31% major-complication rate, reported deaths run about 5 per million users, and the FDA, ACOG, and the AAFP all affirm it is safe and effective through 10 weeks.

Is mifepristone still legal? Yes, as of June 2026. The Supreme Court left it on the market in a 9-0 ruling in June 2024, and in May 2026 it let telehealth and mail access continue while a new challenge proceeds. The drug is still available by prescription, including by telehealth and mail, though that access is still being litigated.

What is the difference between mifepristone and misoprostol? Mifepristone blocks progesterone and stops the pregnancy from continuing. Misoprostol, taken a day or two later, makes the uterus cramp and empty. The two-drug regimen uses both.

Can you get mifepristone by mail? In most cases yes. The FDA allowed mail delivery and telehealth prescriptions starting in December 2021, and by the end of 2024 about 1 in 4 abortions were done by telehealth. Some states are trying to block it.

What you can do

1. Tell Congress to protect the FDA’s scientific authority. Ask your representatives, on the record, to keep drug-approval decisions with the FDA’s scientists rather than the courts or political appointees. Use the letter and call script below.

2. Defend telehealth and mail access for mifepristone. The biggest practical fight is over how the drug is dispensed. Ask your members of Congress to oppose any rule that would force patients back into in-person-only pickup.

3. Oppose reviving the Comstock Act. Tell your representatives to reject any effort to use the 1873 Comstock Act to ban mailing abortion medication. A dormant anti-vice law should not override the FDA.

4. Support state shield laws. If your state has a shield law protecting prescribers, tell your state legislators to keep it. If it does not, ask them to pass one so doctors can serve patients without fear of out-of-state prosecution.

5. Write your representative using the letter below and ask for a clear commitment to keep mifepristone available by telehealth and mail.